Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000522660 | SCV000617487 | likely pathogenic | not provided | 2017-09-28 | criteria provided, single submitter | clinical testing | This variant is denoted FH c.555+1G>A or IVS4+1G>A and consists of a G>A nucleotide substitution atthe +1 position of intron 4 of the FH gene. This variant destroys a canonical splice donor site and is predicted to causeabnormal gene splicing, leading to either an abnormal message that is subject to nonsense-mediated mRNA decay orto an abnormal protein product. This variant has been reported in at least one individual with a personal history ofcutaneous and uterine leiomyomas, and a fumarate hydratase enzyme assay found this variant's activity was reduced,compared to control activity (Badeloe 2006, Muller 2017). Based on the currently available information, we considerFH c.555+1G>A to be a likely pathogenic variant. |
Revvity Omics, |
RCV000522660 | SCV002023003 | pathogenic | not provided | 2020-02-05 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003464109 | SCV004197325 | pathogenic | Fumarase deficiency | 2023-08-31 | criteria provided, single submitter | clinical testing |